Home Cart Sign in  
Chemical Structure| 1204144-28-4 Chemical Structure| 1204144-28-4

Structure of AZD-1208
CAS No.: 1204144-28-4

Chemical Structure| 1204144-28-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases (IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively) and is used for treating AML.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD-1208

CAS No. :1204144-28-4
Formula : C21H21N3O2S
M.W : 379.48
SMILES Code : O=C(NC/1=O)SC1=C/C2=C(N3C[C@H](N)CCC3)C(C4=CC=CC=C4)=CC=C2
InChI Key :MCUJKPPARUPFJM-UWCCDQBKSA-N
Pubchem ID :58423153

Safety of AZD-1208

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AZD-1208

epigenetics
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • Pim3

    Pim3, IC50:1.9 nM

  • Pim1

    Pim1, IC50:0.4 nM

  • Pim2

    Pim2, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 3μM 72 hours AZD1208 significantly reduced the clonogenic survival of MDA-MB-231 cells and increased chemotherapy-induced caspase 3/7 activity. PMC5552044
SUM149 1μM 72 hours AZD1208 significantly reduced the clonogenic survival of SUM149 cells and increased chemotherapy-induced caspase 3/7 activity. PMC5552044
Raji cells 1μM to 10μM 6 days To evaluate the effect of AZD1208 on the proliferation of Raji cells, results showed that Raji cells were mostly resistant to the drug PMC4672512
Ramos cells 1μM to 10μM 6 days To evaluate the effect of AZD1208 on the proliferation of Ramos cells, results showed moderate inhibition of cell growth at 10 μM AZD1208 PMC4672512
OCI-Ly3 cells 1μM to 10μM 6 days To evaluate the effect of AZD1208 on the proliferation of OCI-Ly3 cells, results showed a moderate reduction in cell number at 5 μM and 10 μM AZD1208 PMC4672512
OCI-Ly10 cells 1μM to 10μM 6 days To evaluate the effect of AZD1208 on the proliferation of OCI-Ly10 cells, results showed a reduced cell number already at 1 μM AZD1208 PMC4672512
BV173 cells 3 μM To evaluate the effect of AZD1208 on PIM kinase-regulated pathways in Ph+ ALL cell lines. Results showed that AZD1208 treatment reduced phosphorylation levels of c-MYC, BAD at S112, and 4E-BP1 at T37/46. PMC7100125
SUP-B15 cells 3 μM To evaluate the effect of AZD1208 on PIM kinase-regulated pathways in Ph+ ALL cell lines. Results showed that AZD1208 treatment reduced phosphorylation levels of c-MYC, BAD at S112, and 4E-BP1 at T37/46. PMC7100125
Z181 cells 3 μM To evaluate the effect of AZD1208 on PIM kinase-regulated pathways in Ph+ ALL cell lines. Results showed that AZD1208 treatment reduced phosphorylation levels of c-MYC, BAD at S112, and 4E-BP1 at T37/46. PMC7100125
pMel T cells 3 μM 3 days AZD1208 treatment reduced the glycolytic activity of T cells, increased the Tcm phenotype, and reduced the expression of PD1 and CD38. PMC6361669
Human T cells 3 μM AZD1208 treatment increased the Tcm phenotype in human T cells, reduced the expression of PD1 and CD38, and decreased glycolytic activity. PMC6361669
Ba/F3-ITD 1 μM 24, 48, 72 hours AZD1208 in combination with FLT3 inhibitors significantly inhibited the growth of Ba/F3-ITD cells and increased apoptosis. PMC6444348
MV4–11 1 μM 72 hours AZD1208 in combination with quizartinib significantly increased apoptosis in MV4–11 cells. PMC6444348

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MDA-MB-231 and SUM149 xenograft models Oral 50 mpk Once daily for 4 days AZD1208 significantly inhibited tumor growth in MDA-MB-231 and SUM149 xenograft models and induced an increase in p27-positive cells. PMC5552044
mice NOD/SCID/IL-2R γnull mice oral Entinostat: 20 mg/kg/day (SUM190PT), 5 mg/kg/day (SUM149PT); Pimasertib: 30 mg/kg/day (SUM190PT), 0.5 mg/kg/day (SUM149PT) Once daily for 28 days (SUM190PT), 56 days (SUM149PT) To evaluate the effect of AZD1208 on leukemia progression in Ph+ ALL mouse models. Results showed that the combination of AZD1208 and Sabutoclax significantly suppressed leukemia progression. PMC7100125
Mice B16-F10 melanoma model Intraperitoneal injection 5 or 25 mg/kg once daily, until the end of the experiment The combination of AZD1208 with anti-PD1 antibody significantly improved tumor control and extended the survival of tumor-bearing mice. PMC6361669
CB17 SCID mice MV4–11 subcutaneous xenograft model Oral gavage 10 mg/kg twice daily until the end of the experiment AZD1208 in combination with quizartinib significantly inhibited tumor growth of MV4–11 cells and prolonged survival in mice. PMC6444348

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.18mL

2.64mL

1.32mL

26.35mL

5.27mL

2.64mL

References

 

Historical Records

Categories